RxDoctor Payments Data

Gnanaraj Joseph, MD

Pulmonary Disease · Winston Salem, NCNPI 1700847738

Payments from drug & device makers

$5,287in general payments, 2019–2025

Across 188 payments — averaging $28.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Covidien LP$1K
  • Olympus Corporation Of The Americas$896
  • Actelion Pharmaceuticals US, Inc.$741
  • AstraZeneca$471
  • Boehringer Ingelheim$417
  • GSK$288
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$1,92636%
  • Food & beverage$3,36164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,287 in reported general payments places this provider in the 65th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$50,683
Medicare patients
249
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$24,047
Spiriva RespimatTiotropium Bromide30$18,557
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,062
SymbicortBudesonide/Formoterol Fumarate48$13,844
Advair HfaFluticasone Propion/Salmeterol19$6,981
Arnuity ElliptaFluticasone Furoate13$2,635
Albuterol Sulfate HfaAlbuterol Sulfate36$1,290
Azithromycin24$413
Montelukast Sodium20$185
Esomeprazole Magnesium11$182
Prednisone16$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Symbicort$471$37,89284 claims
GSKTrelegy Ellipta, Arnuity Ellipta$288$19,69833 claims
Boehringer IngelheimSpiriva Respimat$417$18,55730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →